24th European Hematology Assication (EHA) Congress

Measurable residual disease in AML: Reduced-intensity conditioning associated with poorer post-transplant outcomes

Natalia Reoutova, 20190716103727

Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.

$Novel anti-CD47 immunotherapy shows promise in relapsed/refractory lymphoma$

Novel anti-CD47 immunotherapy shows promise in relapsed/refractory lymphoma

Christina Lau, 20190710130955

A first-in-class immunoglobulin G4 (IgG4) antibody targeting CD47 has demonstrated durable responses when used in combination with rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or indolent lymphoma.

Venetoclax may be of benefit to MM patients with t(11;14) translocation

Christina Lau, 20190704042900

New data from the suspended BELLINI study suggest that venetoclax may be of benefit to a subgroup of patients with relapsed/refractory multiple myeloma (R/R MM) with the t(11;14) translocation.